The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

Teiji Kuzuya; Masatoshi Ishigami; Takurou Niinomi; Norihiro Imai; Kouichi Achiwa; Takahiro Arakawa; Keiichi Yamada; Satoshi Nakano; Yoji Ishizu; Takashi Honda; Kazuhiko Hayashi; Tetsuya Ishikawa; Isao Nakano; Yoshiaki Katano; Akihiro Itoh; Yoshiki Hirooka; Hidemi Goto

doi:10.2957/kanzo.54.505

The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

Teiji Kuzuya, Masatoshi Ishigami, Takurou Niinomi, Norihiro Imai, Kouichi Achiwa, Takahiro Arakawa, Keiichi Yamada, Satoshi Nakano, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Yoshiaki Katano, Akihiro Itoh, Yoshiki Hirooka, Hidemi Goto

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

Original language	English
Pages (from-to)	505-506
Number of pages	2
Journal	Kanzo/Acta Hepatologica Japonica
Volume	54
Issue number	7
DOIs	https://doi.org/10.2957/kanzo.54.505
Publication status	Published - 30-05-2013
Externally published	Yes

All Science Journal Classification (ASJC) codes

Hepatology

Access to Document

10.2957/kanzo.54.505

Fingerprint

Dive into the research topics of 'The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma'. Together they form a unique fingerprint.

Cite this

Kuzuya, T., Ishigami, M., Niinomi, T., Imai, N., Achiwa, K., Arakawa, T., Yamada, K., Nakano, S., Ishizu, Y., Honda, T., Hayashi, K., Ishikawa, T., Nakano, I., Katano, Y., Itoh, A., Hirooka, Y., & Goto, H. (2013). The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma. Kanzo/Acta Hepatologica Japonica, 54(7), 505-506. https://doi.org/10.2957/kanzo.54.505

@article{41774be1a5c946239feb2801aa9e104e,

title = "The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma",

abstract = "We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.",

author = "Teiji Kuzuya and Masatoshi Ishigami and Takurou Niinomi and Norihiro Imai and Kouichi Achiwa and Takahiro Arakawa and Keiichi Yamada and Satoshi Nakano and Yoji Ishizu and Takashi Honda and Kazuhiko Hayashi and Tetsuya Ishikawa and Isao Nakano and Yoshiaki Katano and Akihiro Itoh and Yoshiki Hirooka and Hidemi Goto",

year = "2013",

month = may,

day = "30",

doi = "10.2957/kanzo.54.505",

language = "English",

volume = "54",

pages = "505--506",

journal = "Kanzo/Acta Hepatologica Japonica",

issn = "0451-4203",

publisher = "Japan Society of Hepatology",

number = "7",

}

Kuzuya, T, Ishigami, M, Niinomi, T, Imai, N, Achiwa, K, Arakawa, T, Yamada, K, Nakano, S, Ishizu, Y, Honda, T, Hayashi, K, Ishikawa, T, Nakano, I, Katano, Y, Itoh, A, Hirooka, Y & Goto, H 2013, 'The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma', Kanzo/Acta Hepatologica Japonica, vol. 54, no. 7, pp. 505-506. https://doi.org/10.2957/kanzo.54.505

The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma. / Kuzuya, Teiji; Ishigami, Masatoshi; Niinomi, Takurou et al.
In: Kanzo/Acta Hepatologica Japonica, Vol. 54, No. 7, 30.05.2013, p. 505-506.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

AU - Kuzuya, Teiji

AU - Ishigami, Masatoshi

AU - Niinomi, Takurou

AU - Imai, Norihiro

AU - Achiwa, Kouichi

AU - Arakawa, Takahiro

AU - Yamada, Keiichi

AU - Nakano, Satoshi

AU - Ishizu, Yoji

AU - Honda, Takashi

AU - Hayashi, Kazuhiko

AU - Ishikawa, Tetsuya

AU - Nakano, Isao

AU - Katano, Yoshiaki

AU - Itoh, Akihiro

AU - Hirooka, Yoshiki

AU - Goto, Hidemi

PY - 2013/5/30

Y1 - 2013/5/30

N2 - We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

AB - We investigated the relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma (HCC). Subjects were 64 patients who began sorafenib therapy. Contrast enhanced CT images were taken at baseline and after 2 weeks of sorafenib treatment. In patients with fever, the ratio of patients demonstrating the disappearance or decrease of lesion contrast on contrast enhanced CT images was significantly higher than in those without fever (91.3% and 61.0%, respectively, p=0.010, Fisher's exact probability test). The results suggested the relationship between the fever and contrast change on contrast enhanced CT.

UR - http://www.scopus.com/inward/record.url?scp=84940340371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940340371&partnerID=8YFLogxK

U2 - 10.2957/kanzo.54.505

DO - 10.2957/kanzo.54.505

M3 - Article

AN - SCOPUS:84940340371

SN - 0451-4203

VL - 54

SP - 505

EP - 506

JO - Kanzo/Acta Hepatologica Japonica

JF - Kanzo/Acta Hepatologica Japonica

IS - 7

ER -

The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this